- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05143970
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (CHANCES)
CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
The trial will be conducted in two parts, Part I- Dose escalation: This part aims to identify the maximum tolerated dose (MTD) of IPH5301 agent in monotherapy and recommended phase 2 dose (RP2D) for future trials, followed by a safety expansion study part cohort.
Part II- Expansion cohort: A total of 12 HER2+ cancer patients, respectively 6 breast cancer patients and 6 gastric cancer patients, is planned to be enrolled into the next expansion cohort to select a recommended dose of IPH5301 to be administered in combination with chemotherapy and trastuzumab for evaluation in future trials with selected advanced solid tumors.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: DOMINIQUE GENRE
- Phone Number: 0491223778
- Email: drci.up@ipc.unicancer.fr
Study Locations
-
-
-
Marseille, France
- Recruiting
- Institut Paoli Calmettes
-
Contact:
- Anthony Gonçalves, MD PhD
- Email: goncalvesa@ipc.unicancer.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Patients with incurable advanced and/or metastatic cancer.
Patients with any of the following cancers:
- In dose escalation: carcinoma of the breast, stomach, esophagus, pancreas, endometrium, ovary or lung.
- In cohort expansion (HER2-positive): carcinoma of the breast and gastric/gastro-esophageal that express HER2 (2 cohorts) . Eligibility is based on HER2 overexpression as determined locally.
Prior treatment with at least one prior systemic therapy in the advanced metastatic setting
- Dose escalation: no limit on number of prior systemic therapies and considered as failing standard therapeutic alternatives and candidate to a phase I study by a multi-disciplinary tumor board.
- Cohort expansion: patients must have previously re-ceived (or be considered as non-eligible to) all authorized standard treatments
- Breast cancer: patient must have received prior (or be considered as ineligible to) trastuzumab pertuzumab, trastuzumab emtansine, trastuzumab deruxtecan and capecitabine+anti-HER2 (trastuzumab, lapatinib or trastuzumab tucatinib) according to label.
- Gastric cancer: patient must have received (or be con-sidered as ineligible to) prior treatment with platinum salts and trastuzumab.
- Presence of at least one measurable lesion by RECIST outside of the CNS.
- At least 18 years of age.
- ECOG performance status of ≤1.
- For patients included in cohort expansion, adequate echocar-diogram, with a left ventricular ejection fraction ≥55%. Patients with a history of LVEF decline (< 50%) on anti-HER2 treatment will not be allowed to participate.
- For patients included in the cohort expansion, feasibility of obtaining tumor biopsy at study entry.
- All non-hematological AEs related to prior therapy must have completely resolved or improved to Grade 1 prior to screening for this study (except for alopecia).
Exclusion Criteria:
- Prior treatment with other monoclonal antibodies or small mol-ecules targeting CD73 or the adenosine pathway.
- Patients with known spinal cord compression.
- Patients with grade 2 or higher peripheral neuropathy.
- Symptomatic, untreated, or actively progressing central nerv-ous system (CNS) metastases. Patients with suspected CNS involvement at screening should have an magnetic resonance imaging (MRI) (preferred) or computed tomography (CT) each preferably with IV contrast of the brain prior to study entry to rule them out. Asymptomatic patients with treated CNS lesions are eligible, provided that definied criteria are met
- Known allergic reactions attributed to compounds of similar product.
- Patients with dyspnea at rest and history of pneumonit-is/interstitial lung disease.
- Patients with any serious underlying medical condition that would impair the subject from receiving or tolerating the planned treatment.
- Concurrent enrollment in another clinical trial, unless it is an non-interventional clinical study or the follow-up period of an interventional study.
- Any concurrent treatment with any anti-cancer agents or drugs that could have anti-tumor effects.
- Active auto-immune disease within the past 2 years.
- ≥ Grade 3 immune related AE or an immune-related neuro-logic or ocular AE of any grade while receiving prior immunotherapy.
- Subjects who have undergone major surgery <28 days prior to starting study drug.
- Treatment with any conventional or investigational anticancer therapy within 28 days prior to day 1 of study treatment.
- Receipt of live attenuated vaccine or SARS-CoV-2 vaccine within 30 days prior to the first dose of study drug
- Primary immunodeficiency and/or history of allogenic transplantation.
- Current uncontrolled infection.
- Hepatitis B, C or HIV-positive patients.
- Subjects with a history of other active invasive malignancies during the past three years with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer).
- Pregnant or breastfeeding women.
- Participants with abnormal coagulation profiles or any history of coagulopathy within the 6 months prior to the first dose of IMP, as well as history of deep vein thrombosis, pulmonary embolism, cerebrovascular accident or other arterial thrombus. Participants being treated with an anticoagulant (eg, warfarin or heparin) for a thrombotic event that occurred more than 6 months before en-rollment, or for an otherwise stable and allowed medical condition (eg, well-controlled atrial fibrillation), provided that dose and co-agulation parameters (as defined by local standard of care) are stable for at least 1 month prior to the first dose of IMP are allowed.
- Subjects with dementia or altered mental status that would preclude understanding and rendering of informed consent document.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IPH5301 administration
Part I- Dose escalation: Escalating dose levels of IPH5301 will be evaluated. Part II-Cohort Expansion: IPH5301 will be administrated in combination with trastuzumab and paclitaxel |
Part I-Dose escalation Patients will receive IPH5301 alone on day 1 (Week 1). Treatment will be administered every 2 weeks until progression or unacceptable toxicity or other reasons requiring treatment discon-tinuation, for a maximum duration of 12 months. Part II- Expansion cohort Patients will receive IPH5301 at a recommended dose (RP2D) or a next lower dose (RP2D-1)in combination with trastuzumab and paclitaxel, at day 1 and every 2 weeks up to 6 cycles of paclitaxel. The RP2D dose will not exceed the designated maximum tolerated dose (MTD). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of dose limiting toxicity (DLT) of IPH5301 in monotherapy in the dose escalation and in combination with paclitaxel and trastuzumab in the expansion cohort
Time Frame: 1 month
|
DLTs would include any grade 3 toxicity or higher that occurs during the first 4 weeks from the first injection of IPH5301, with the some exceptions
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Anthony GONCALVES, MD PhD, Institut Paoli-Calmettes
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Endocrine System Diseases
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Ovarian Neoplasms
- Endometrial Neoplasms
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Trastuzumab
Other Study ID Numbers
- CHANCES-IPC 2021-008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Cancer
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedGIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic CancerFrance
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Institut de Cancérologie de la LoireSaint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand ParisWithdrawnMetastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck CancerFrance
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
Cedars-Sinai Medical CenterRecruitingNeoplasms | Cancer | Cancer, MetastaticUnited States
-
Cota Inc.Blue Cross Blue Shield; NantHealth Inc.TerminatedPancreatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Prostate Cancer | Metastatic Colon CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Oslo University HospitalVestre Viken Hospital Trust; University Hospital of North Norway; Ostfold Hospital... and other collaboratorsRecruitingCancer MetastaticNorway
Clinical Trials on IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
-
Shen LinUnknownColorectal Cancer | Esophageal Squamous Cell Carcinoma | Biliary Tract Cancer | Targeted Therapy | HER2China
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAsthma | Healthy ParticipantsAustralia
-
Fudan UniversityRecruitingMetastatic Breast Cancer | HER2-positive Breast CancerChina
-
Centre Francois BaclesseGRECANCompleted
-
Swiss Group for Clinical Cancer ResearchRecruitingNon-small Cell Lung Cancer (NSCLC) | Stage IVSwitzerland
-
Fondazione Italiana Linfomi - ETSRoche Pharma AGNot yet recruiting
-
Genelux CorporationCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal CarcinomatosisUnited States
-
Tang-Du HospitalCompletedSintilimab and Anlotinib in Combination With ChemotherapyChina
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisRecruitingMuscle Invasive Bladder CancerUnited States, China
-
Maastricht Radiation OncologyRecruitingHead and Neck CancerNetherlands